Centaurus Biopharma Co., Ltd.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Astrazeneca Ab

Petrochina Company Limited

Centaurus Biophrama Co., Ltd.

Yuliang Li

Lainyungang Runzhong Pharmaceutical Co., Ltd.

Yongxin Han

Yong Peng

Hong Luo

Yuandong Hu

Dengming Xiao

Hui Zhang

Li Zhu

Xijie Liu

Yinghui Sun

Na Zhao

Shanchun Wang

Fansheng Kong

Xiquan Zhang

Ling Yang

Hongjiang Xu

Yan Zhu

Rui Zhao

Liguang Dai

Xiaowei Duan

Xinhe Xu

Xin Tian

Yanqing Yang

Huting Wang

Shulong Wang

Bo Liu

Zhe Wang

He Wang

Xinlu Li

Rong Yu

Wei Hu

Wei Wu

Bin Wang

Zhihua Liu

Yong Hu

Yu Shen

Weigang Huang

Kenneth L Arrington

Zhao Yang

Peter J Mohr

Qiong Wu

Michelle Lamb

Aiming Zhang

Zhi Liang

Tao Wang

Honghao Yu

Ying Sun

Dingwei Yu

Meng Guo

Chuanyu Zhang

Jijun Li

Feng Gong

Zanping Wang

Xizhe Li

Yuanyuan Huang

Quan Hu

Ruiyu Zhao

Xianxing Shang

Xuan Xu

Xiaofeng Zhai

Jian Sun

Guangzhen Chu

Yongheng Wei

Yunhe Su

Shousong Cao

Zhaobai Zhong

Yunsheng Wei

Yujin Wan

Yangjian Liu

Mei Liu

Kuncheng Chen

Chunyan Jiao

Zhenhua Guo

Haifa Tang

Chun Sing Li

Yunfu Luo

Mehul Patel

Jiayi Xu

The invention provides a physical simulation experimental device and method for water invasion and drainage gas recovery in gas reservoir, and the experimental device includes: a heterogeneous reservoir model having a first core holder, a second core holder, a third core holder and a fourth core holder, wherein the third core holder is connected between the first core holder and the second core holder, and the fourth core holder is connected between an outlet end of the first core holder and an outlet end of the second core holder; a gas injection mechanism having a gas injection bottle and a gas injection cylinder; a water body simulation mechanism having a water storage tank and a water injection pump. The invention can simulate and reveal different drainage gas recovery modes, timings, scales and their influences on the recovery ratio of the gas reservoir.

Physical simulation experimental device and method for water invasion and drainage gas recovery in gas reservoirs

An iridinesulfonamide compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity, pharmaceutically acceptable salts, solvates or hydrates thereof, a pharmaceutical composition, as well as use of the compound or the pharmaceutically acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition thereof in treating IDH1 mutation induced cancer. 

Iridinesulfonamide compound and use method thereof

Provided are a sultam compound having isocitrate dehydrogenase 1 (IDH1) inhibitory activity as represented by formula I or pharmaceutically-acceptable salts, solvates or hydrates thereof, a preparation method thereof, and a pharmaceutical composition containing the compound. The compound or the pharmaceutically-acceptable salts, solvates or hydrates thereof, and the pharmaceutical composition containing the compound can be used to treat IDH1 mutation-induced cancers. 

Sultam compound and application method thereof

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals. 

Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor

Disclosed are compounds having formulae I and II or pharmaceutically acceptable salts or hydrates thereof, a preparation method thereof and pharmaceutical compositions thereof. The compounds having formulae I and II possesses an isocitrate dehydrogenase 2 (IDH2) inhibitory activity and are capable of treating IDH2 mutation-induced cancers. 

1,3,5-triazine derivative and method of using same

A pyrrolopyrimidine comprising a cyclopentyi substituent. The present invention specifically relates to a compound represented by formula. A and a stereoisomer and pharmaceutically acceptable salt thereof. The invention further relates to a method for manufacturing the pyrrolopyrimidine comprising the cyclopentyl substituent represented by formula A, a pharmaceutical composition, and an application of the compound in treating a disease induced by Janus kinase. 

Pyrrolopyrimidine comprising cyclopentyl substituent

The present invention belongs to the field of pharmaceutical chemistry, and relates to a substituted pyrrolopyrimidine CDK inhibitor, in particular to a compound as shown in formula I or a pharmaceutically acceptable salt or solvate thereof, as well as a preparation method thereof and a pharmaceutical composition thereof. The present invention also relates to the use of the compound and the pharmaceutical composition thereof in the preparation of a drug for treating diseases associated with CDK inhibition. The compound according to the present invention has a marked inhibitory effect on CDK, excellent drug absorption and significantly superior oral absorption effect. 

Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof

The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase. 

Pyrrolopyrimidine compound

The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.

Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal

The present disclosure relates to aniline pyrimidine derivatives or pharmaceutically acceptable salts thereof as EGFR inhibitors, specifically relates to compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions, the method and uses thereof for treating EGFR mediated diseases. 

N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity

The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical compositions thereof. The compounds represented by general formula (I), general formula (II) or general formula (III) have inhibitory activities against isocitrate dehydrogenase 2 (IDH2), thereby being capable of treating IDH2 mutation-induced cancers. 

Antitumor compound targeting IDH2 mutation and method of use thereof

The present application relates to a substituted amino six-membered saturated heteroalicycle represented by formula I as a long-acting DPP-IV inhibitor, a method for preparing the same, a pharmaceutical composition comprising the same, and a use of the same in treating and/or preventing diseases and disorders benefitting from DPP-IV inhibition. 

Substituted amino six-membered saturated heteroalicycles as long-acting DPP-IV inhibitors

Provided are a compound represented by formula (III) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (III), and the application of the pharmaceutical compositions as selective inreversible inhibitor of Bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with aberrant B cell proliferation and cancers. 

Inhibitor of bruton's tyrosine kinase

The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.

Pyridine-substituted 2-aminopyridine protein kinase inhibitors

The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolite, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and are further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provides the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans. 

Inhibitors of bruton's tyrosine kinase

Growing community of inventors

Beijing, China

Yongxin Han